Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion
Benzinga
Johnson & Johnson reported strong Q4 2025 results with adjusted earnings of $2.46 per share (up 20.6% YoY) and sales of $24.56 billion (up 9.1% YoY), both beating consensus expectations. The company issued 2026 guidance of $99.50-$100.5 billion in sales and adjusted earnings of $11.43-$11.63 per share. Growth was driven by oncology drugs like Darzalex and Carvykti, and immunology products, though Stelara sales declined significantly.
Continue Reading